Respiratory Inhaler Devices Market: By Product Type (Metered Dose Inhaler, Nebulizer, Dry Powder Inhaler), By Technology (Manually Operated Inhalers, Digitally Operated Inhalers), By Disease Indication (Asthma, Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Arterial Hypertension, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography


Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Respiratory Inhaler Devices Market size was valued at USD 29.2 billion in 2022 and is poised to grow at a CAGR of 4.8% from 2023-29. Respiratory Inhaler Devices are the medical devices that deliver the medication to prevent or control the chronic obstructive pulmonary disease (COPD), asthma, and other respiratory disorders. Various types of respiratory inhaler devices are available in the market such as metered dose inhaler, dry powder inhaler, and nebulizer. Escalation in the number of industries led to an abnormal increase in environmental pollution that causes respiratory diseases such as COPD and asthma might propel the market. According to World Health Organization approximately 3 Mn deaths were observed in 2015 around the globe. Increase in the tobacco consumption majorly in middle and low income countries may causes respiratory disorders and which in turn drive the market. Moreover, most of the market players are focusing on the development of newer respiratory inhaler devices which are more convenient for drug administration. Furthermore, acquisitions and mergers, product approvals, and product launchings are the strategies followed by market players for garnering larger revenue share in market. For instance, in April 2016, AstraZeneca received FDA approval for Bevepsi Aeresphere (glycopyrrolate and formoterol fumarate) inhalation aerosol used in chronic obstructive pulmonary disease (COPD). In addition, in January 2016, Novartis AG collaborated with Qualcomm, Inc. for the innovation of digital technology for the Breezhaler inhaler used in the treatment of COPD. For instance, in August 2014, Sandoz received Mexico's Health Authority (COFEPRIS) approval for the marketing of Airflusal Forspiro used in COPD. Middle East and Africa market driven by product launchings by the market players in Africa region.

Respiratory Inhaler Devices Market Key Developments:
  • In January 2017, Cipla launched the respiratory inhaler Synchrobreathe in South Africa. Moreover, an increase in tobacco consumption and an increase in pollution due to an increasing number of industries are anticipated to boost the market in the region.

Global Respiratory Inhaler Devices Market Summary

Study Period


Base Year




Largest Market

North America

Fastest Growing Market

North America
Respiratory Inhaler Devices Market Dynamics

Increase in the prevalence of COPD, asthma, and other respiratory disorder, technological advancements in respiratory inhaler devices, rapid industrialization and rise in smoking population are anticipated to fuel the market. Moreover, ease of administration of drug with respiratory inhaler devices, cost-effective of the products, and growing newborn babies and geriatric population who often exposed to one or the other respiratory disorders are anticipated to boost the respiratory inhaler devices market over the forecast period. However, adverse effects associated with drug inhalation, product recalls, lack of single effective inhalers for all types of disease, and lack of awareness about respiratory inhalers in underdeveloped countries expected to hamper the growth of the market over the forecast timeframe.

Key Features of the Reports

  • The respiratory inhaler devices market report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Global Respiratory Inhaler Devices Market Segmentation

By Product Type
  • Metered Dose Inhaler
  • Nebulizer
  • Dry Powder Inhaler
By Technology
  • Manually Operated Inhalers
  • Digitally Operated Inhalers
By Disease Indication
  • Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Pulmonary Arterial Hypertension
  • Others
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Frequently Asked Questions

The respiratory inhaler devices market size was valued at USD 29.2 billion in 2022

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

The respiratory inhaler devices market key players are Cipla Ltd. (India) Beximco Pharmaceuticals Ltd. (Bangladesh) Merck & Co., Inc. (U.S.) GlaxoSmithKline plc (U.K.) AstraZeneca plc (U.K.) Boehringer Ingelheim GmbH (Germany) Koninklijke Philips N.V. (Netherlands) Teva Pharmaceutical Industries Ltd. (Israel)

  • Cipla Ltd. (India)
  • Beximco Pharmaceuticals Ltd. (Bangladesh)
  • Merck & Co., Inc. (U.S.)
  • GlaxoSmithKline plc (U.K.)
  • AstraZeneca plc (U.K.)
  • Boehringer Ingelheim GmbH (Germany)
  • Koninklijke Philips N.V. (Netherlands)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • OMRON Healthcare Europe B.V. (Netherlands)
  • Novartis AG (Switzerland)
  • PARI Medical Holding GmbH (Germany)